Literature DB >> 24532422

Genomic and transcriptional alterations of cholangiocarcinoma.

Takeshi Ito1, Mika Sakurai-Yageta, Akiteru Goto, Chawalit Pairojkul, Puangrat Yongvanit, Yoshinori Murakami.   

Abstract

Cholangiocarcinoma (CCA) is one of the representative cancers refractory to any therapeutic approach. The incidence of CCA is highest in the northeastern part of Thailand, where chronic inflammation caused by liver fluke (Opisthorchis viverrini: Ov) infection is a major etiologic factor. The incidence of CCA is also increasing in other countries, including Japan. Here, we overview the genetic and transcriptional alterations of CCA with and without association with Ov infection. CCA with Ov shows enhanced expression of the genes involved in xenobiotic metabolism and chronic inflammatory responses, including cytokine signaling, whereas CCA without Ov shows enhanced expression of growth factor signaling, such as HER2. Exome and the following prevalence sequencing identified mutations of the BAP1, ARID1A, IDH1 and IDH2 genes in CCA, in addition to the high incidence of known mutations in the TP53, KRAS2 SMAD4, and CDKN2A genes, suggesting the role of chromatin modulators in CCA pathogenesis. CCA with Ov shows significantly higher incidence of the TP53 gene mutation, whereas CCA without Ov showed significantly more frequent mutations of the BAP1, IDH1 and IDH2 genes. However, CCAs with Ov and without Ov share a similar mutation spectrum dominated by C : G > T : A transitions mainly at CpG dinucleotides, suggesting that CCA shares etiologic factors with pancreatic ductal carcinoma but not with hepatocellular carcinoma. Comprehensive analyses of the genetic and transcriptional alterations of CCA with and without Ov infection would provide useful information for the prevention, early diagnosis, and treatment of CCA.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Cholangiocarcinoma; KRAS; Liver fluke; Opisthorchis viverrini; TP53

Mesh:

Year:  2014        PMID: 24532422     DOI: 10.1002/jhbp.67

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  13 in total

Review 1.  Molecular diagnosis of intrahepatic cholangiocarcinoma.

Authors:  Hiroaki Haga; Tushar Patel
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-29       Impact factor: 7.027

2.  High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection.

Authors:  Attapol Titapun; Vor Luvira; Tharatip Srisuk; Apiwat Jareanrat; Vasin Thanasukarn; Malinee Thanee; Prakasit Sa-Ngiamwibool; Sureerat Padthaisong; Kassaporn Duangkumpha; Manida Suksawat; Watcharin Loilome; Paiboon Sithithaworn; Anchalee Techasen; Bandit Thinkhamrop; Alexa Dzienny; Ayse Caglayan; David Park; Simran Mahmud; Narong Khuntikeo
Journal:  Int J Gen Med       Date:  2021-06-01

3.  Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.

Authors:  Malinee Thanee; Sureerat Padthaisong; Manida Suksawat; Hasaya Dokduang; Jutarop Phetcharaburanin; Poramate Klanrit; Attapol Titapun; Nisana Namwat; Arporn Wangwiwatsin; Prakasit Sa-Ngiamwibool; Narong Khuntikeo; Hideyuki Saya; Watcharin Loilome
Journal:  Cancer Metab       Date:  2021-03-16

4.  microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway.

Authors:  Pengfei Qiao; Guodong Li; Wen Bi; Lianmeng Yang; Lei Yao; Dequan Wu
Journal:  BMC Cancer       Date:  2015-06-16       Impact factor: 4.430

5.  CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.

Authors:  Malinee Thanee; Watcharin Loilome; Anchalee Techasen; Eiji Sugihara; Shogo Okazaki; Shinya Abe; Shiho Ueda; Takashi Masuko; Nisana Namwat; Narong Khuntikeo; Attapol Titapun; Chawalit Pairojkul; Hideyuki Saya; Puangrat Yongvanit
Journal:  Cancer Sci       Date:  2016-06-20       Impact factor: 6.716

6.  Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans.

Authors:  L Che; B Fan; M G Pilo; Z Xu; Y Liu; A Cigliano; A Cossu; G Palmieri; R M Pascale; A Porcu; G Vidili; M Serra; F Dombrowski; S Ribback; D F Calvisi; X Chen
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

Review 7.  Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.

Authors:  Fuliang Qian; Junping Guo; Zhi Jiang; Bairong Shen
Journal:  Int J Biol Sci       Date:  2018-05-22       Impact factor: 6.580

8.  New era with the genetic assessment for biliary tree cancers beyond the anatomical assessment alone.

Authors:  Hiromitsu Hayashi; Hideo Baba
Journal:  Ann Transl Med       Date:  2020-06

9.  Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma.

Authors:  Keun Soo Ahn; Koo Jeong Kang; Yong Hoon Kim; Tae-Seok Kim; Bong-Il Song; Hae Won Kim; Daniel O'Brien; Lewis R Roberts; Jeong Woo Lee; Kyoung Sook Won
Journal:  Ann Surg Treat Res       Date:  2019-03-28       Impact factor: 1.859

Review 10.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.